Showing results (21-30 of 214) with videos related to

Sort By:
Pageof 22
Clinical Lung Cancer|April 28, 2006
Bronchioloalveolar carcinoma: a reviewDan J Raz, Biao He, Rafael Rosell, et al.
Cancers|May 30, 2020
The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)Ping-Chih Hsu, Cheng-Ta Yang, David M Jablons, et al.
Cancer Letters|April 20, 2005
Wnt signaling in lung cancerJulien Mazieres, Biao He, Liang You, et al.
Clinical Lung Cancer|February 18, 2004
Future directions: oncolytic virusesLiang You, Biao He, Zhidong Xu, et al.
Cancer|March 10, 2007
Update on the molecular biology of malignant mesotheliomaAmie Y Lee, Dan J Raz, Biao He, et al.
Scientific Reports|June 24, 2017
Systematic comparison of two whole-genome amplification methods for targeted next-generation sequencing using frozen and FFPE normal and cancer tissuesPedro Mendez, Li Tai Fang, David M Jablons, et al.
Biomedicines|December 15, 2018
The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic CancerPing-Chih Hsu, Cheng-Ta Yang, David M Jablons, et al.
Molecular Cancer Therapeutics|June 21, 2008
Evaluation of a chemical library of small-molecule Dishevelled antagonists that suppress tumor growth by down-regulating T-cell factor-mediated transcriptionLiang You, Zhidong Xu, Chandanamali Punchihewa, et al.
Translational Lung Cancer Research|July 18, 2017
Drug development against the hippo pathway in mesotheliomaGavitt A Woodard, Yi-Lin Yang, Liang You, et al.
International Journal of Molecular Sciences|August 8, 2019
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)Ping-Chih Hsu, David M Jablons, Cheng-Ta Yang, et al.
Pageof 22